{"id":44569,"date":"2025-10-27T21:22:47","date_gmt":"2025-10-27T13:22:47","guid":{"rendered":"https:\/\/flcube.com\/?p=44569"},"modified":"2025-10-27T21:22:48","modified_gmt":"2025-10-27T13:22:48","slug":"gsk-secures-global-rights-to-syndivias-adc-for-metastatic-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44569","title":{"rendered":"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer"},"content":{"rendered":"\n

British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK<\/a>) and Syndivia announced on October 27, 2025, that they have entered into an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical Antibody-Drug Conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).<\/p>\n\n\n\n

Innovative ADC Technology<\/strong>
The ADC leverages Syndivia’s next-generation GeminiMab conjugation technology, demonstrating enhanced anti-tumor activity and a promising safety profile. Preclinical studies indicate the ADC can shrink tumors effectively without a proportional increase in significant side effects, even at higher doses, highlighting its potential as a best-in-class therapy.<\/p>\n\n\n\n

Collaboration Terms<\/strong>
Under the agreement, Syndivia will receive an upfront payment, development and commercial milestone payments totaling up to \u00a3268 million, and tiered royalties on future product sales. GSK will take full responsibility for the ADC program’s development, manufacturing, and global commercialization.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that…<\/p>\n","protected":false},"author":1,"featured_media":44572,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,16,278,184,914],"class_list":["post-44569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-cancer","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"\nGSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that they have entered into an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical Antibody-Drug Conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44569\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that they have entered into an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical Antibody-Drug Conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44569\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T13:22:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T13:22:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer\",\"datePublished\":\"2025-10-27T13:22:47+00:00\",\"dateModified\":\"2025-10-27T13:22:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569\"},\"wordCount\":146,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2703.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44569#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44569\",\"name\":\"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2703.webp\",\"datePublished\":\"2025-10-27T13:22:47+00:00\",\"dateModified\":\"2025-10-27T13:22:48+00:00\",\"description\":\"British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that they have entered into an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical Antibody-Drug Conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44569\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2703.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44569#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer - Insight, China's Pharmaceutical Industry","description":"British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that they have entered into an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical Antibody-Drug Conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44569","og_locale":"en_US","og_type":"article","og_title":"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer","og_description":"British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that they have entered into an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical Antibody-Drug Conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).","og_url":"https:\/\/flcube.com\/?p=44569","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-27T13:22:47+00:00","article_modified_time":"2025-10-27T13:22:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44569#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44569"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer","datePublished":"2025-10-27T13:22:47+00:00","dateModified":"2025-10-27T13:22:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44569"},"wordCount":146,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44569#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2703.webp","keywords":["ADC \/ XDC","Cancer","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44569#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44569","url":"https:\/\/flcube.com\/?p=44569","name":"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44569#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44569#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2703.webp","datePublished":"2025-10-27T13:22:47+00:00","dateModified":"2025-10-27T13:22:48+00:00","description":"British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that they have entered into an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical Antibody-Drug Conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44569#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44569"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44569#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2703.webp","width":1080,"height":608,"caption":"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44569#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Secures Global Rights to Syndivia\u2019s ADC for Metastatic Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44569"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44569\/revisions"}],"predecessor-version":[{"id":44573,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44569\/revisions\/44573"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44572"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}